207 related articles for article (PubMed ID: 34128322)
1. Effectiveness and safety of oral anticoagulation treatment beyond 1 year after venous thromboembolism in patients at intermediate recurrence risk.
Johnsen SP; Rasmussen TB; Falstie-Jensen AM; Harboe L; Stynes G; Dybro L; Hansen ML; Brandes A; Grove EL; Münster AM
Basic Clin Pharmacol Toxicol; 2021 Sep; 129(3):210-220. PubMed ID: 34128322
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
4. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
Raskob G; Ageno W; Cohen AT; Brekelmans MP; Grosso MA; Segers A; Meyer G; Verhamme P; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
Lancet Haematol; 2016 May; 3(5):e228-36. PubMed ID: 27132697
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes of Direct Oral Anticoagulants vs Warfarin for Extended Treatment of Venous Thromboembolism.
Fang MC; Reynolds K; Fan D; Prasad PA; Sung SH; Portugal C; Garcia E; Go AS
JAMA Netw Open; 2023 Aug; 6(8):e2328033. PubMed ID: 37581888
[TBL] [Abstract][Full Text] [Related]
6. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
[TBL] [Abstract][Full Text] [Related]
7. Trajectories of Oral Anticoagulation Adherence and Associated Clinical Outcomes During Long-Term Anticoagulation Among Medicare Beneficiaries With Venous Thromboembolism.
Park H; Jones BL; Huang PL; Kang HR; Dietrich EA; DeRemer CE; Lo-Ciganic WH
Ann Pharmacother; 2023 Dec; 57(12):1349-1360. PubMed ID: 36999519
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism.
Coleman CI; Turpie AGG; Bunz TJ; Beyer-Westendorf J
J Thromb Thrombolysis; 2018 Oct; 46(3):339-345. PubMed ID: 29881958
[TBL] [Abstract][Full Text] [Related]
9. Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism.
Kohn CG; Bunz TJ; Beyer-Westendorf J; Coleman CI
Eur J Haematol; 2019 Feb; 102(2):143-149. PubMed ID: 30328143
[TBL] [Abstract][Full Text] [Related]
10. Risk factors of thrombotic recurrence and major bleeding in patients with intermediate-risk for recurrence of venous thromboembolism.
Yamashita Y; Amano H; Morimoto T; Kadota K; Hata R; Matsushita K; Osakada K; Sano A; Takase T; Hiramori S; Kim K; Oi M; Akao M; Kobayashi Y; Toyofuku M; Inoko M; Tada T; Chen PM; Murata K; Tsuyuki Y; Nishimoto Y; Sasa T; Sakamoto J; Kinoshita M; Togi K; Mabuchi H; Takabayashi K; Kato T; Ono K; Kimura T;
J Thromb Thrombolysis; 2022 Jan; 53(1):182-190. PubMed ID: 34228248
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and Safety of Direct Oral Anticoagulants vs. Warfarin and Recurrence After Discontinuation in Patients With Acute Venous Thromboembolism in the Real World.
Hara N; Lee T; Nozato T; Terui Matsuyama M; Okata S; Nagase M; Mitsui K; Nitta G; Watanabe K; Miyazaki R; Nagamine S; Kaneko M; Nakamura T; Nagata Y; Miyamoto T; Obayashi T; Ashikaga T
Circ J; 2022 May; 86(6):923-933. PubMed ID: 34645732
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis.
Dawwas GK; Dietrich E; Smith SM; Davis K; Park H
Clin Ther; 2020 Sep; 42(9):e161-e176. PubMed ID: 32768247
[TBL] [Abstract][Full Text] [Related]
13. Risk Factors for Major Bleeding during Prolonged Anticoagulation Therapy in Patients with Venous Thromboembolism: From the COMMAND VTE Registry.
Kim K; Yamashita Y; Morimoto T; Kitai T; Yamane T; Ehara N; Kinoshita M; Kaji S; Amano H; Takase T; Hiramori S; Oi M; Akao M; Kobayashi Y; Toyofuku M; Izumi T; Tada T; Chen PM; Murata K; Tsuyuki Y; Saga S; Sasa T; Sakamoto J; Kinoshita M; Togi K; Mabuchi H; Takabayashi K; Shiomi H; Kato T; Makiyama T; Ono K; Furukawa Y; Kimura T;
Thromb Haemost; 2019 Sep; 119(9):1498-1507. PubMed ID: 31230344
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism.
Dawwas GK; Smith SM; Dietrich E; Lo-Ciganic WH; Park H
Am J Health Syst Pharm; 2020 Jan; 77(3):188-195. PubMed ID: 31974557
[TBL] [Abstract][Full Text] [Related]
15. Association between anticoagulant treatment duration and risk of venous thromboembolism recurrence and bleeding in clinical practice.
Kaatz S; Fu AC; AbuDagga A; LaMori J; Bookhart BK; Damaraju CV; Tan H; Schein J; Nutescu E
Thromb Res; 2014 Oct; 134(4):807-13. PubMed ID: 25127013
[TBL] [Abstract][Full Text] [Related]
16. One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events.
Chen SY; Wu N; Gulseth M; LaMori J; Bookhart BK; Boulanger L; Fields L; Schein J
J Manag Care Pharm; 2013 May; 19(4):291-301. PubMed ID: 23627575
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data.
Costa OS; Beyer-Westendorf J; Ashton V; Milentijevic D; Moore KT; Bunz TJ; Coleman CI
J Thromb Thrombolysis; 2021 Feb; 51(2):349-358. PubMed ID: 32588288
[TBL] [Abstract][Full Text] [Related]
18. Risk of cancer after anticoagulation in patients with unprovoked venous thromboembolism: an observational cohort study.
Eischer L; Kammer M; Traby L; Kyrle PA; Eichinger S
J Thromb Haemost; 2017 Jul; 15(7):1368-1374. PubMed ID: 28407356
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis.
Cohen A; Keshishian A; Lee T; Wygant G; Rosenblatt L; Hlavacek P; Mardekian J; Wiederkehr D; Sah J; Luo X
Thromb Haemost; 2021 Mar; 121(3):383-395. PubMed ID: 33171521
[TBL] [Abstract][Full Text] [Related]
20. Anticoagulation Therapy for Venous Thromboembolism in the Real World - From the COMMAND VTE Registry.
Yamashita Y; Morimoto T; Amano H; Takase T; Hiramori S; Kim K; Konishi T; Akao M; Kobayashi Y; Inoue T; Oi M; Izumi T; Takahashi K; Tada T; Chen PM; Murata K; Tsuyuki Y; Sakai H; Saga S; Sasa T; Sakamoto J; Yamada C; Kinoshita M; Togi K; Ikeda T; Ishii K; Kaneda K; Mabuchi H; Otani H; Takabayashi K; Takahashi M; Shiomi H; Makiyama T; Ono K; Kimura T;
Circ J; 2018 Apr; 82(5):1262-1270. PubMed ID: 29576597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
